Please ensure Javascript is enabled for purposes of website accessibility

Corporation for Public Broadcasting to Close After Funding Cut, in Blow to Local Media

2 days ago

‘Freedom Week’: California Gun Owners Rush to Buy Ammo After Court Ruling

2 days ago

Wall Street Selloff Sparked by Trump Tariffs, Amazon Results, Weak Payrolls

2 days ago

US Construction Spending Extends Decline in June

2 days ago

Global Shares in Red After US Jobs Data, Trump’s Tariff Salvo

2 days ago

Construction of $200M Trump Ballroom at the White House to Begin in September

3 days ago

US Senate Committee Backs $1 Billion for Ukraine in Pentagon Spending Bill

3 days ago

Trump Says Mexico Trade Deal Extended for 90 Days

3 days ago

Fresno Unified Trustee Susan Wittrup Responds to $162,000 Payout

4 days ago
Panel Endorses Widespread Use of Pfizer COVID-19 Vaccine in US
gvw_ap_news
By Associated Press
Published 5 years ago on
December 10, 2020

Share

A government advisory panel endorsed widespread use of Pfizer’s coronavirus vaccine Thursday, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.

In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and older.

That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

Despite all the remaining unknowns, in an emergency, “the question is whether you know enough,” said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia, who concluded that the shot’s potential potential benefits outweigh its risks.

The independent review by non-government experts in vaccine development, infectious diseases and medical statistics was considered critical to boosting Americans’ confidence in the safety of the shot, which was developed at breakneck speed less than a year after the virus was identified.

The decision came as COVID-19 cases surge to ever-higher levels across the U.S., with deaths hitting an all-time, one-day high of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But initial supplies will be limited and reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until the shots become widely available on demand, something that will probably not happen until the spring.

The FDA Next Week Will Review a Second Vaccine

Experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start get back to normal and Americans can put away their masks.

The FDA next week will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require just one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University

All eyes now turn to the FDA staff scientists who will make the final decision on whether to greenlight use of the Pfizer-BioNTech vaccine. Regulators not only in Britain but in Canada have already approved it for use in their countries, and President Donald Trump and White House officials have complained for weeks about the pace of FDA’s careful review.

FDA’s vaccine director Dr. Peter Marks said ahead of the expert meeting that a decision would come within “days to a week.”

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” FDA Commissioner Stephen Hahn said before the meeting.

A positive vote for the vaccine was virtually assured after FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

It Is Not Yet Clear if It Can Stop the Silent, Symptomless Spread

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of COVID-19, the FDA’s advisers stressed it is not yet clear if it can stop the silent, symptomless spread that accounts for up to half of cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

And the advisers are worried that Pfizer will lose its opportunity to answer critical questions as it begins offering the real vaccine to study participants who had been getting dummy shots.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities since studies in tens of thousands of people can’t detect rare risks that strike 1 in a million. Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine for now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the COVID-19 vaccine from giving it a try, and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

India Will Buy Russian Oil Despite Trump’s Threats, Officials Say

DON'T MISS

The US Said It Had No Choice but to Deport Them to a Third Country. Then It Sent Them Home

DON'T MISS

Trump Reaffirms Support for Morocco’s Sovereignty Over Western Sahara

DON'T MISS

Fresno’s Dog Daze Fest Returns With The Chainsmokers Headlining

DON'T MISS

Willow the Streetwise Poodle Mix Gets a Second Chance

DON'T MISS

Newsom Wants Voters to Weigh In on New Congressional Districts in November

DON'T MISS

Kia America Recalls 201,149 US Telluride Vehicles

DON'T MISS

US Reviewing Visa Denial for Venezuelan Little League Players, State Department Says

DON'T MISS

Hamas Says It Won’t Disarm Unless Independent Palestinian State Established

DON'T MISS

Gifford Fire Grows to 23,588 Acres in Santa Barbara, San Luis Obispo Counties

UP NEXT

Trump Reaffirms Support for Morocco’s Sovereignty Over Western Sahara

UP NEXT

Kia America Recalls 201,149 US Telluride Vehicles

UP NEXT

US Reviewing Visa Denial for Venezuelan Little League Players, State Department Says

UP NEXT

US Judges Speak Out About Death Threats, ‘Swattings,’ and ‘Pizza Doxings’

UP NEXT

Trump Fires US Labor Department’s Statistical Leader After Weaker Than Expected Jobs Report

UP NEXT

Corporation for Public Broadcasting to Close After Funding Cut, in Blow to Local Media

UP NEXT

Trump Eyes Bringing Azerbaijan, Central Asian Nations Into Abraham Accords, Sources Say

UP NEXT

Ghislaine Maxwell Moved From Florida Prison to Lower-Security Facility

UP NEXT

Trump Escalates Trade War With Canada Following Palestine Stance

UP NEXT

US Construction Spending Extends Decline in June

Fresno’s Dog Daze Fest Returns With The Chainsmokers Headlining

19 hours ago

Willow the Streetwise Poodle Mix Gets a Second Chance

19 hours ago

Newsom Wants Voters to Weigh In on New Congressional Districts in November

20 hours ago

Kia America Recalls 201,149 US Telluride Vehicles

20 hours ago

US Reviewing Visa Denial for Venezuelan Little League Players, State Department Says

20 hours ago

Hamas Says It Won’t Disarm Unless Independent Palestinian State Established

20 hours ago

Gifford Fire Grows to 23,588 Acres in Santa Barbara, San Luis Obispo Counties

21 hours ago

Fresno Donates Firefighting Gear to Sister City Guadalajara

21 hours ago

Corruption Scandal Puts Mexico’s President on Defense Against Trump

21 hours ago

US Judges Speak Out About Death Threats, ‘Swattings,’ and ‘Pizza Doxings’

2 days ago

India Will Buy Russian Oil Despite Trump’s Threats, Officials Say

NEW DELHI — Indian officials said Saturday that they would keep purchasing cheap oil from Russia despite a threat of penalties from Presiden...

16 hours ago

A view shows oil pump jacks outside Almetyevsk in the Republic of Tatarstan, Russia June 4, 2023. (Reuters File)
16 hours ago

India Will Buy Russian Oil Despite Trump’s Threats, Officials Say

A Lao man deported from the U.S. holds up his non-national ID card - a document that defines his legal status in the country he left behind decades ago, and to which he has now returned, in Vientiane, Laos, July 31, 2025. REUTERS/Phoonsab Thevongsa
17 hours ago

The US Said It Had No Choice but to Deport Them to a Third Country. Then It Sent Them Home

President Donald Trump boards Air Force One on his way to New Jersey from Joint Base Andrews, Maryland, U.S., August 1, 2025. (Reuters File)
18 hours ago

Trump Reaffirms Support for Morocco’s Sovereignty Over Western Sahara

19 hours ago

Fresno’s Dog Daze Fest Returns With The Chainsmokers Headlining

After surviving more than six months alone on the streets, a 15-pound poodle mix named Willow is now safe and learning to trust humans again. (Mell's Mutts)
19 hours ago

Willow the Streetwise Poodle Mix Gets a Second Chance

California Governor Gavin Newsom speaks to the press after a hearing on the use of National Guard troops amid federal immigration sweeps, at the California State Supreme Court in San Francisco, California, U.S., June 12, 2025. (Reuters FIle)
20 hours ago

Newsom Wants Voters to Weigh In on New Congressional Districts in November

2025 Kia Telluride is displayed during the Los Angeles Auto Show, in Los Angeles, California, U.S., November 21, 2024. (Reuters File)
20 hours ago

Kia America Recalls 201,149 US Telluride Vehicles

Venezuelan baseball player Abraham Gutierrez, a member of Cacique Mara, a baseball youth team that will not be participating in the 2025 Little League World Series after their U.S. visa was denied, prepares for a practice session in Maracaibo, Venezuela, August 1, 2025. REUTERS/Gaby Oraa TPX IMAGES OF THE DAY
20 hours ago

US Reviewing Visa Denial for Venezuelan Little League Players, State Department Says

Help continue the work that gets you the news that matters most.

Search

Send this to a friend